Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.52 |
| ▸ | CA1 | P00915 | 12/20 | 0.52 |
| ▸ | CA9 | Q16790 | 7/20 | 0.52 |
| ▸ | CA12 | O43570 | 6/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.52 |
| ▸ | CA7 | P43166 | 3/20 | 0.52 |
| ▸ | CA3 | P07451 | 2/20 | 0.52 |
| ▸ | CA6 | P23280 | 2/20 | 0.52 |
| ▸ | CA5A | P35218 | 2/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25516405 | 0.85 | KMT2A (0.57) | CA2CA1CA9CA12CA14 | |
| SCHEMBL21962679 | 0.84 | CA2 (0.50) | CA2CA1CA9CA12CA14 | |
| SCHEMBL3497043 | 0.81 | MAPT (0.52) | CYP2C19KMT2A | |
| SCHEMBL18300622 | 0.81 | ALDH1A1 (0.45) | KMT2A | |
| SCHEMBL21962388 | 0.80 | CA2 (0.59) | CA2CA1CA9CA12CA14 | |
| SCHEMBL25516350 | 0.80 | CA2 (0.51) | CA2CA1CA9CA12CA14 | |
| SCHEMBL176221 | 0.79 | ELANE (0.52) | — | |
| SCHEMBL15578026 | 0.78 | PTGS2 (0.46) | CA2CA1CA9CA12CA14 | |
| SCHEMBL3637984 | 0.78 | CA2 (0.55) | CA2CA1CA9CA12CA14 | |
| SCHEMBL283836 | 0.77 | CA2 (0.70) | CA2CA1CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| WO-2025024521-A1 | SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| EP-3880659-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| WO-2023083343-A1 | POLYCYCLIC COMPOUNDS AND METHODS THEREOF | HEPAITECH (BEIJING) BIOPHARMA TECHNOLOGY CO., LTD. (CN) | 2023-05-19 | — | — | WO | disclosed |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| EP-3880659-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CA2 1210/4885CA1 3732/4885CA9 2927/4885 |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | CA2 4119/4885CA1 4864/4885CA9 4694/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | CA2 4112/4885CA1 4863/4885CA9 4688/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | CA2 4119/4885CA1 4864/4885CA9 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.